FindTrial
Sign In

Study on the dominant population of tacrolimus in the treatment of myasthenia gravis

Study on the dominant population of tacrolimus in the treatment of myasthenia gravis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057193
Enrollment
Unknown
Registered
2022-03-02
Start date
2022-03-02
Completion date
Unknown
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myasthenia gravis

Interventions

Experimental group:Tacrolimus

Sponsors

Shijiazhuang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 90 Years

Inclusion criteria

Inclusion criteria: Myasthenia gravis patients with a definite diagnosis.

Exclusion criteria

Exclusion criteria: 1. Patients with severe medical diseases: severe arrhythmia, severe pulmonary disease, ALT/AST> 2 times of normal value, Cr> 2 times of normal value; 2. Patients with MGFA stage of IVb or V; 3. Patients with malignant tumors (excluding thymoma), a history of HIV infection or severe immunodeficiency; 4. Pregnant or breastfeeding patients; 5. Patients with a history of mental illness; 6. Tuberculosis patients with positive tuberculin test or T-SPOT test.

Design outcomes

Primary

MeasureTime frame
Objective response rate;Disease control rate;Influence factor;Adverse reaction;—

Countries

China

Contacts

Public ContactQi Guoyan

Shijiazhuang People's Hospital

qiguoyan1106@sina.com+86 17603119295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026